Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has progressed on Androgen Receptor Pathway Inhibitor (ARPI). The main questions it aims to answer are: * Does talazoparib plus enzalutamide improve efficacy in metastatic castration resistant prostate cancer (mCRPC) compared to enzalutamide alone? * What is the time to disease progression \[radiographic, Prostate Specific Antigen (PSA), clinical\] in participants treated with talazoparib plus enzalutamide after progression on abiraterone? * What medical problems do participants have when receiving talazoparib plus enzalutamide? Researchers will compare the combination of talazoparib and enzalutamide as a first-line treatment for mCRPC to see if the combination improves the PSA response rate and delays progression compared to enzalutamide alone. The safety and tolerability of the combination (talazoparib and enzalutamide) will also be studied
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyzna w wieku 18 lat lub starszy
- •Potwierdzony rozpoznaniem histologiczne raka gruczolistego prostaty
- •Chętny do podpisania zgody na udział w badaniu
- •Sprawny stan zdrowia umożliwiający uczestnictwo w badaniu (ECOG 0-1)
- •Rak prostaty z przerzutami potwierdzonymi badaniami (scyntygrafia kostna, tomografia lub rezonans)
- •Bez objawów lub minimalne objawy raka na początku badania
- •Spodziewana długość życia co najmniej 6 miesięcy
- •Trwająca terapia obniżająca poziom testosteronu (chyba że pacjent miał usunięte jądra)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (19)
Institut Bergonié
Bordeaux, France
Hôpital Universitaire de Brest
Brest, France
Centre Oscar Lambret
Lille, France
Hôpital Saint Joseph
Paris, France
Hôpitaux Universitaire de Strasbourg
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Institut Català d'Oncologia (ICO)
Badalona, Spain
Hospital del Mar
Barcelona, Spain
Hospital Clínico y Provincial de Barcelona
Barcelona, Spain
Consorcio Corporación Sanitaria Parc Taulí
Sabadell, Spain
Hospital Universitario Marqués de Valdecilla
Santander, Spain
Hospital Universitario de Jerez de la Frontera
Cadiz, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital 12 de Octubre
Madrid, Spain
Hospital Universitario La Paz
Madrid, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Hospital Universitario Cruces
Barakaldo, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Hospital Fundación Jiménez Díaz
Madrid, Spain
Trial contact
Luis Gonzaga Paz-Ares Rodríguez
Elena Castro, Dra.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.